AGT — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9294927	0.74	4/20
SCHEMBL9294944	0.74	4/20
SCHEMBL9295030	0.74	4/20
SCHEMBL9295066	0.74	4/20
SCHEMBL9295022	0.72	4/20
SCHEMBL9295027	0.72	4/20
SCHEMBL9295706	0.72	4/20
SCHEMBL9386316	0.70	4/20
SCHEMBL9386321	0.70	4/20
SCHEMBL9308051	0.67	4/20
SCHEMBL9295424	0.64	4/20
SCHEMBL9295430	0.64	4/20
SCHEMBL9295025	0.63	4/20
SCHEMBL9295031	0.63	4/20
SCHEMBL9295226	0.63	4/20
SCHEMBL9295316	0.63	4/20
SCHEMBL9384947	0.63	4/20
SCHEMBL9295272	0.61	4/20
SCHEMBL9295278	0.61	4/20
SCHEMBL9295715	0.61	4/20

Clinical trials — most relevant to AGT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers	PHASE4	COMPLETED
Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension	PHASE4	COMPLETED
Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent	PHASE4	COMPLETED
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension	PHASE4	COMPLETED
Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension	PHASE3	COMPLETED
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension	PHASE3	COMPLETED
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension	PHASE3	COMPLETED
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension	PHASE2	COMPLETED
Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I	PHASE1/PHASE2	COMPLETED
ACE Inhibition and Novel Cardiovascular Risk Factors	PHASE2	COMPLETED
: Vascular Function in Health and Disease	PHASE1	RECRUITING
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications	PHASE1	UNKNOWN
Expression and Function of the Renin-Angiotensin System in the Esophagus	EARLY_PHASE1	COMPLETED
Angiotensinogen Gene and Human Hypertension	nan	COMPLETED
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy	nan	COMPLETED
Angiotensinogen Gene and Hypertension	nan	UNKNOWN
Study of Polymorphisms of RAAS and MMPs in Acute Heart Failure	nan	COMPLETED
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19	nan	UNKNOWN
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker	nan	UNKNOWN
Residual Renal Function Preservation in Peritoneal Dialysis Patients	nan	UNKNOWN
Racial Variation in ACE--Genetic and Physiologic Bases	nan	COMPLETED
Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.	nan	UNKNOWN
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)	nan	COMPLETED
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome	nan	UNKNOWN
Renin-Angiotensin System Inhibitors and COVID-19	nan	UNKNOWN
New Biomarkers and Difficult-to-treat Hypertension	nan	COMPLETED
Angiotensinogen Variants and Adverse Pregnancy Outcomes	nan	COMPLETED
The Role of Angiotensinogen Gene Polymorphism in the Pathogenesis of Non-familial Sick Sinus Syndrome	nan	UNKNOWN
Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease	nan	COMPLETED
Non-invasive Haemodynamic Assessment in Hypertension	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AGT binder may also engage these)

Protein	Name	Similarity
Q9GLP6	—	1.000	Q9GLP6 →
Q9GLN8	—	1.000	Q9GLN8 →
Q9TSZ0	—	1.000	Q9TSZ0 →
P01015	—	0.992	P01015 →
P01017	—	0.992	P01017 →
P11859	—	0.991	P11859 →
P20757	—	0.989	P20757 →
P97290	—	0.981	P97290 →
P50448	—	0.980	P50448 →
Q6P734	—	0.977	Q6P734 →
P05155	—	0.974	P05155 →
B0UYL8	—	0.970	B0UYL8 →
P05546	—	0.968	P05546 →
P47776	—	0.968	P47776 →
Q5RDA8	—	0.966	Q5RDA8 →
Q61247	—	0.965	Q61247 →
Q9UK55	—	0.965	Q9UK55 →
Q62975	—	0.964	Q62975 →
Q8R121	—	0.962	Q8R121 →
Q64268	—	0.961	Q64268 →
P49182	—	0.961	P49182 →
A8MV23	—	0.960	A8MV23 →
Q95121	—	0.959	Q95121 →
SERPINE1	Plasminogen activator inhibitor 1	0.959	landscape →
P31211	—	0.958	P31211 →
P36955	—	0.955	P36955 →
Q7TMF5	—	0.954	Q7TMF5 →
Q5I2A0	—	0.953	Q5I2A0 →
P97298	—	0.953	P97298 →
P23276	—	0.952	P23276 →